Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 316

Similar articles for PubMed (Select 12118570)

1.
2.
3.

Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.

Lord EM, Harwell L, Koch CJ.

Cancer Res. 1993 Dec 1;53(23):5721-6.

4.

Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia.

Bergeron M, Evans SM, Sharp FR, Koch CJ, Lord EM, Ferriero DM.

Neuroscience. 1999;89(4):1357-66.

PMID:
10362320
5.

2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors.

Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ.

Cancer Res. 1996 Jan 15;56(2):405-11.

6.
7.

Hypoxia in human intraperitoneal and extremity sarcomas.

Evans SM, Hahn SM, Magarelli DP, Zhang PJ, Jenkins WT, Fraker DL, Hsi RA, McKenna WG, Koch CJ.

Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):587-96.

PMID:
11173159
8.

Immunocytochemical labelling of aerobic and hypoxic mammalian cells using a platinated derivative of EF5.

Matthews J, Adomat H, Farrell N, King P, Koch C, Lord E, Palcic B, Poulin N, Sangulin J, Skov K.

Br J Cancer Suppl. 1996 Jul;27:S200-3.

9.

Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status.

Evans SM, Jenkins WT, Shapiro M, Koch CJ.

Adv Exp Med Biol. 1997;411:215-25.

PMID:
9269430
10.
11.

EF5 binding and clinical outcome in human soft tissue sarcomas.

Evans SM, Fraker D, Hahn SM, Gleason K, Jenkins WT, Jenkins K, Hwang WT, Zhang P, Mick R, Koch CJ.

Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):922-7.

PMID:
16458778
12.

In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors.

Mahy P, De Bast M, Gallez B, Gueulette J, Koch CJ, Scalliet P, Grégoire V.

Radiother Oncol. 2003 Apr;67(1):53-61.

PMID:
12758240
14.

Immunohistochemical detection of changes in tumor hypoxia.

Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1177-86. doi: 10.1016/j.ijrobp.2008.12.004.

15.

Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.

Laughlin KM, Evans SM, Jenkins WT, Tracy M, Chan CY, Lord EM, Koch CJ.

J Pharmacol Exp Ther. 1996 May;277(2):1049-57.

PMID:
8627516
16.

Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation.

Evans SM, Hahn SM, Magarelli DP, Koch CJ.

Am J Clin Oncol. 2001 Oct;24(5):467-72.

PMID:
11586098
17.

The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.

Wang J, Foehrenbacher A, Su J, Patel R, Hay MP, Hicks KO, Wilson WR.

Clin Cancer Res. 2012 Mar 15;18(6):1684-95. doi: 10.1158/1078-0432.CCR-11-2296. Epub 2011 Dec 13.

18.
19.
20.

Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker.

Waleh NS, Brody MD, Knapp MA, Mendonca HL, Lord EM, Koch CJ, Laderoute KR, Sutherland RM.

Cancer Res. 1995 Dec 15;55(24):6222-6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk